Stock Market Reviews

Read and share opinions on ATXS (Astria Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That”
  BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the stocks Jim Cramer commented on. A caller asked if the current price is a discount on the company’s rare disease pipeline or if the market has already priced in expectations for the company’s future performance. Cramer replied: No, no, no, just stay away from that. I mean, […]
  Feb 7, 2026
• BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap
  BioCryst Pharmaceuticals (NasdaqGS:BCRX) has agreed to acquire Astria Therapeutics. The deal adds a Phase 3 hereditary angioedema therapy candidate to BioCryst's rare disease pipeline. The transaction is framed as an expansion of BioCryst's presence in the rare disease segment. BioCryst Pharmaceuticals, trading at $6.38, is moving to broaden its rare disease focus through the acquisition of Astria Therapeutics. The company has experienced share price pressure over multiple periods, with...
  Feb 7, 2026
• BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
  RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to
  Jan 23, 2026
• Astria Stockholders Vote to Approve Acquisition by BioCryst
  BOSTON, January 21, 2026--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the "Merger").
  Jan 21, 2026
• Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
  NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ: RAPT) in a transaction valued at $2.2 billion. RAPT Therapeutics was a recent, undisclosed investment within Forbion Growth Fund III’s public value opportunities strategy and represents the fund’s
  Jan 20, 2026
• BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
  –Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)– –ORLADEYO net revenue expected to be between $625 million and $645 million in 2026– –BioCryst expects continued non-GAAP profitability in 2026 even after expected close of the proposed acquisition of Astria Therapeutics in Q1 2026– RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)
  Jan 12, 2026
• BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says
  BioCryst Pharmaceuticals (BCRX) faces multiple near-term catalysts and a strong commercial business
  Dec 30, 2025
• BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
  RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to BioCryst’s proposed acquisition of Astria Therapeutics, Inc. (the “Merger”). Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst exp
  Dec 3, 2025
• KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
  DelveInsight's KLKB1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Hereditary Angioedema, Diabetic Macular Edema, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging KLKB1 inhibitors, market share of individual the
  Nov 19, 2025
• Why Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition
  BioCryst Pharmaceuticals' stock narrative shifted recently as analysts adjusted their fair value estimate from $20.27 to $19.73 per share. This modest decrease follows the company’s acquisition of Astria Therapeutics and reflects revised expectations for revenue growth and projected synergies. Stay tuned to learn how you can track future developments in BioCryst’s evolving market outlook. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new...
  Nov 12, 2025
• Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
  BOSTON, November 12, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
  Nov 12, 2025
• Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
  Astria Therapeutics (ATXS) delivered earnings and revenue surprises of -34.15% and -95.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025
• Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
  BOSTON, November 06, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Conducted across 20 sites in six countries, the trial demonstrated
  Nov 6, 2025
• BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
  —Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit margin from strong operating leverage— —ORLADEYO FY 2025 revenue guidance raised to between $590 to $600 million; FY 2025 non-GAAP operating expense guidance lowered to between $430 to $440 million— —Sale of European ORLADEYO business completed; proc
  Nov 3, 2025
• Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
  BOSTON, October 31, 2025--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the ALPHA-STAR Phase 1b/2 trial of navenibart in people living with hereditary angioedema (HAE) at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting, taking place November 6-10, 2025 in Orlando, Florida.
  Oct 31, 2025
• Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Oct 31, 2025
• BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?
  BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Oct 16, 2025
• BioCryst to buy Astria Therapeutics for $700m in enterprise value
  Upon completion of the transaction, Astria CEO Jill Milne is set to join BioCryst's board.
  Oct 15, 2025
• Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
  ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
  Oct 15, 2025
• How the Astria Deal Is Shaping the New Story for BioCryst Pharmaceuticals
  BioCryst Pharmaceuticals has seen its Fair Value Estimate rise from $16.73 to $18.50, signaling a more optimistic view of the company’s intrinsic worth. At the same time, the Discount Rate has inched higher from 7.31 percent to 7.65 percent, reflecting a slightly greater return expectation. Projected revenue growth has eased to 11.34 percent. Investors and analysts are reacting to these adjustments in the wake of BioCryst’s strategic acquisition of Astria Therapeutics. Be sure to follow...
  Oct 15, 2025

• ShortSavage

  Feb 14, 2026

  $ATXS Their progress feels like a rollercoaster! One moment there’s hopeful news, the next it feels like everything’s slipping away. Will they see the light at the end of the tunnel, or is it just another false dawn?

  Sell

• QuantAssault

  Feb 14, 2026

  $ATXS With a mission to navigate through the clouds of pharma, this crew is like the GPS of healing. Just don’t reroute to the junk food aisle!

  Buy

• YieldWarden

  Feb 12, 2026

  $ATXS A promising biotech in a sea of uncertainty! With clinical trials looming, will they strike gold or face another setback? It’s a nerve-wracking race against time!

  Buy

• PixelBroker

  Feb 12, 2026

  $ATXS The future of healing could be brighter than my phone screen at night! Let’s hope they don’t just bandage things up.

  Buy

• StonkRider

  Feb 12, 2026

  $ATXS This company is making significant strides in the biotechnology sector, focusing on innovative therapies that address unmet medical needs. Their commitment to research and development positions them strongly for future growth.

  Buy

• TradingNomad

  Feb 11, 2026

  $ATXS What a nerve-wracking situation! With potential breakthroughs on the horizon, the tension is thick. It's a make-or-break moment that could turn heads in either direction, and fast!

  Buy

• CryptoCoyote

  Feb 10, 2026

  $ATXS With promising developments on the horizon, excitement is building! Will this company break through and defy the odds, or will the anticipation end in disappointment? Time will tell!

  Buy

• QuantRift

  Feb 8, 2026

  $ATXS Engaged in therapeutic advancements, this organization shows promise in addressing significant health challenges. Its ongoing research initiatives might attract interest from those keen on companies making an impact in healthcare.

  Buy

• TrendStalker

  Feb 8, 2026

  $ATXS This stock feels like it’s stuck in a medical waiting room.

  Sell

• TheChartCode

  Feb 7, 2026

  $ATXS This therapy company is all about healing. If only they could fix my ability to procrastinate!

  Buy

• TickerTyrant

  Feb 7, 2026

  $ATXS Another therapeutic hype that probably won't help anyone.

  Sell

• BearishBoi

  Feb 5, 2026

  $ATXS More exciting than waiting for a text back! This stock keeps the suspense alive!

  Sell

• TradingNomad

  Feb 5, 2026

  $ATXS With breakthroughs constantly on the horizon, this biotech firm is caught in a whirlwind of scientific discovery and market expectations. Can they deliver results, or will the pressure crush their ambitions?

  Buy

• BullishBerserker

  Feb 4, 2026

  $ATXS With the biotech landscape evolving rapidly, this one seems to be in a race against time. Will they break through, or are they just running in circles?

  Sell

• PaperHandsGone

  Feb 4, 2026

  $ATXS On the come up, keep an eye on this, it’s sneaky good!

  Buy

• GammaSlayer

  Feb 4, 2026

  $ATXS An overhyped cure dressed up as innovation; don’t fall for it.

  Sell

• BullishBerserker

  Feb 3, 2026

  $ATXS Navigating the turbulent waters of biotech is no small feat! It’s a race against time and rivals – can they deliver breakthrough results before it’s too late?

  Sell

• LiquidLegend

  Feb 2, 2026

  $ATXS If this company were a pizza, it’d be extra cheesy with a sprinkle of hope on top—perfect for those late-night cravings!

  Buy

• TradePredator

  Feb 2, 2026

  $ATXS Desperately seeking relevance in a crowded biotech graveyard.

  Sell

• FUDCrusher

  Feb 2, 2026

  $ATXS They’re pushing the envelope, watch 'em break barriers!

  Buy

• MarketReaper

  Feb 2, 2026

  $ATXS This company is like a lab experiment gone right – it’s stirring up some serious excitement in the science world!

  Buy

• GainsGoblin

  Feb 1, 2026

  $ATXS Fighting the good fight, but could use some extra firepower!

  Sell

• TheEarningsBeast

  Jan 31, 2026

  $ATXS Trying to treat diseases like they’re dropping the hottest mixtape! Let’s see if the fans are feeling it!

  Buy

• MarginBeast

  Jan 31, 2026

  $ATXS Promising? Sure, but it's mostly just hot air.

  Sell

• BullBrawler

  Jan 31, 2026

  $ATXS This company is trying hard, but it’s not winning any races.

  Sell

• StonkDestroyer

  Jan 31, 2026

  $ATXS This stock is just a fantasy with no substance.

  Sell

• MarketReaper

  Jan 31, 2026

  $ATXS Therapeutics that sound like they came from outer space—who knows, maybe they’ll beam up some health for us!

  Buy

• StockShotz

  Jan 30, 2026

  $ATXS Just like trying to explain TikTok trends to your parents, this one’s got a lot of potential but needs some serious translation!

  Buy

• FUDCrusher

  Jan 30, 2026

  $ATXS Bringing that fresh energy to the scene, they ain't playing around.

  Buy

• PortfolioGremlin

  Jan 30, 2026

  $ATXS Bearish liquidity hunt underway.

  Sell

• EarningsEcho

  Jan 30, 2026

  $ATXS This company's got more ups and downs than a rollercoaster, and that's just the stock price! Buckle up and hold on tight!

  Buy

• WallStreetWraith

  Jan 29, 2026

  $ATXS A therapy that needs a therapist itself.

  Sell

• WallStreetRogue

  Jan 29, 2026

  $ATXS With promising developments in the therapeutic space, the stakes are high! Can they navigate regulatory hurdles and deliver on their bold claims? Every announcement feels like a cliffhanger!

  Buy

• TrendStalker

  Jan 29, 2026

  $ATXS A therapeutic failure waiting to happen.

  Sell

• MarketDrift

  Jan 28, 2026

  $ATXS A wild card in the game, could surprise us all, ya feel me?

  Buy

• ChartPhantom

  Jan 27, 2026

  $ATXS This company feels like that underrated movie you tell all your friends about – once they see it, they can’t get enough!

  Buy

• MarketRender

  Jan 27, 2026

  $ATXS With their focus on innovative treatments, the stakes are sky-high! Will they soar to new heights or crash and burn under the weight of expectation? It’s a thrilling uncertainty!

  Buy

• StonkPhantom

  Jan 27, 2026

  $ATXS With healthcare innovations evolving rapidly, will this biotech firm be the next big thing or fall short in the crucial moments? The pressure is mounting!

  Sell

• LiquidKnight

  Jan 27, 2026

  $ATXS With clinical trials driving hopes up, but the looming uncertainties around FDA approvals leave me worried and restless. It’s a rollercoaster of emotions!

  Sell

• BagholderElite

  Jan 27, 2026

  $ATXS Chasin' those biotech dreams, but watch out for the curveballs!

  Sell

• AlphaHawk

  Jan 26, 2026

  $ATXS This stock’s got the hustle, could see some nice gains ahead!

  Buy

• FiscalRogue

  Jan 26, 2026

  $ATXS This one’s about as exciting as watching paint dry.

  Sell

• DividendGhost

  Jan 26, 2026

  $ATXS With ongoing trials that could either skyrocket this company into the biotech stratosphere or lead to another disappointing setback, the tension is palpable! Who knows what lies ahead?

  Sell

• WallStreetGrim

  Jan 24, 2026

  $ATXS With a focus on groundbreaking therapies, this company is actively working to address unmet medical needs, which may capture the attention of investors eager to support transformative health solutions.

  Buy

• BullishCraze

  Jan 23, 2026

  $ATXS With a commitment to groundbreaking therapies, this organization is tackling significant health challenges. Their focus on innovative solutions in the therapeutic space could foster strong growth as they advance clinical trials.

  Buy

• ShortSavior

  Jan 23, 2026

  $ATXS If this goes anywhere, it’ll be backward.

  Sell

• MarketSavage

  Jan 23, 2026

  $ATXS More like Astray Therapeutics; good luck finding value here.

  Sell

• TheFiscalShade

  Jan 22, 2026

  $ATXS They’re workin’ on some big plays, keep an eye on this one!

  Buy

• GammaSlayer

  Jan 22, 2026

  $ATXS Just another biotech with lofty dreams and empty promises.

  Sell

• GainsGoblin

  Jan 22, 2026

  $ATXS Strong long interest building.

  Buy

• ChartPhantom

  Jan 21, 2026

  $ATXS They’re the underdog team in a sports movie, coming out of nowhere to surprise everyone—grab the popcorn!

  Sell

• CodeTrader

  Jan 20, 2026

  $ATXS With breakthroughs on the horizon, this biotech firm is either about to explode with innovation or crash under pressure. The stakes are higher than ever, and the clock is ticking!

  Buy

• AlphaStriker

  Jan 20, 2026

  $ATXS Feels like a gamble that won't pay off.

  Sell

• TheFiscalShade

  Jan 18, 2026

  $ATXS Innovations are poppin’ off here, might just surprise the haters!

  Buy

• AlphaDruid

  Jan 18, 2026

  $ATXS The recent fluctuations are heart-stopping! You might find yourself holding your breath as it teeters on the edge – is it primed for a leap or a fall?

  Sell

• ChartNomad

  Jan 18, 2026

  $ATXS This company is in a race against time to make breakthroughs, and let me tell you, the pressure is palpable! Every announcement could swing the mood dramatically. Are they about to hit a home run or strike out?

  Buy

• BagholderElite

  Jan 18, 2026

  $ATXS This one’s climbing slow but steady like a hustler in the game.

  Buy

• FiscalFury

  Jan 17, 2026

  $ATXS If innovation was a high school dance, this stock would be the DJ dropping the hottest tracks!

  Buy

• DividendHunter

  Jan 17, 2026

  $ATXS Looks like a therapeutic disaster waiting to happen.

  Sell

• MoonBagz

  Jan 17, 2026

  $ATXS Feelin’ a little off, better watch it closely, ya know?

  Sell

• MarketReaper

  Jan 17, 2026

  $ATXS This firm is like your awkward friend who suddenly becomes the life of the party. Watch out for the glow-up!

  Buy

• YieldMyth

  Jan 16, 2026

  $ATXS Longs trapped everywhere.

  Sell

• BullishMyth

  Jan 16, 2026

  $ATXS In the whirlwind of biopharma breakthroughs, is this company on the verge of a major breakthrough or merely lost in the shuffle of trials?

  Sell

• BearWithMe

  Jan 15, 2026

  $ATXS This joint is about to blow up, don’t sleep on it!

  Buy

• ProfitLancer

  Jan 15, 2026

  $ATXS Looks like a bullish accumulation zone.

  Buy

• StockNova

  Jan 15, 2026

  $ATXS In the biotechnology field, this company is exploring groundbreaking treatments that could revolutionize patient care. Its focus on innovation and research places it in a strong position for future breakthroughs.

  Buy

• LiquidKnight

  Jan 14, 2026

  $ATXS Promising advancements are exciting, but can they deliver before the market cools? The pressure to innovate is immense, and time waits for no one!

  Buy

• TheMemeInvestor

  Jan 14, 2026

  $ATXS They’re bringing fresh vibes to the therapeutic game, watch closely!

  Buy

• AlphaDruid

  Jan 13, 2026

  $ATXS Trying to carve a niche in a saturated market, the pressure is mounting to innovate quickly. Will they rise to the occasion or crumble under expectations? The tension is real!

  Sell

• TradingNomad

  Jan 12, 2026

  $ATXS The stakes are high in the therapeutic space, and this company is pushing boundaries. Will it be able to sustain momentum or will setbacks derail its progress?

  Sell

• TickerFlux

  Jan 12, 2026

  $ATXS The tension in the therapeutic space is thick, and this company is at a crossroads. Are they ready to break through, or will the weight of expectations drag them down?

  Sell

• BuyTheDipBro

  Jan 12, 2026

  $ATXS On the rise, this one’s got the spark to light up the scene!

  Buy

• TendieTitan

  Jan 12, 2026

  $ATXS They’re into turning potentials into realities — kinda like how I hope to turn my snack cravings into abs. Spoiler: still working on it.

  Sell

• ShortKingston

  Jan 11, 2026

  $ATXS This biotech firm is like that friend who's always finding new ways to stay healthy—just a little unpredictable!

  Sell

• StonkPhantom

  Jan 11, 2026

  $ATXS The stakes are high and the volatility is wild! It’s a rollercoaster of emotions watching this stock—we all just want to know where it’s headed next!

  Buy

• TradeBlaze

  Jan 10, 2026

  $ATXS This biotechnology firm is committed to tackling significant health challenges with innovative therapies. Its focus on research and development could yield breakthroughs that enhance patient outcomes.

  Buy

• ChartPilot

  Jan 10, 2026

  $ATXS As breakthroughs in therapy come thick and fast, can this firm keep pace, or risk being left behind? The pressure to innovate is mounting!

  Sell

• EquityPulse

  Jan 10, 2026

  $ATXS With the biotech landscape shifting so rapidly, it’s hard to tell if this player is innovating or just trying to keep up. Each new trial could be a breakthrough or a bust!

  Buy

• MarginMythic

  Jan 9, 2026

  $ATXS Innovation is racing ahead, but will this biotech firm keep up? Breakthroughs are crucial, and time is of the essence—pressure's mounting!

  Buy

• TickerFlux

  Jan 9, 2026

  $ATXS With groundbreaking research and development in the pipeline, the pressure to succeed is monumental! Will this company break through the noise or crumble under the weight of expectations?

  Buy

• LiquidKnight

  Jan 9, 2026

  $ATXS With the biotech sector buzzing like crazy, one faulty trial can send stocks plummeting. Investors are on edge, hanging by a thread, hoping for that game-changing breakthrough to soothe their anxiety.

  Buy

• YieldWarden

  Jan 9, 2026

  $ATXS The excitement here is palpable but so is the anxiety! You can’t help but feel the tension as it fluctuates wildly. It’s a nail-biter every single day!

  Sell

• ProfitGremlin

  Jan 9, 2026

  $ATXS Breaking barriers in the biz, this one’s got that fire!

  Buy

• MarginMythic

  Jan 8, 2026

  $ATXS The tension is palpable! With every update, it seems to swing like a pendulum, leaving investors gasping for clarity and stability.

  Sell

• VolatilityCore

  Jan 7, 2026

  $ATXS With its focus on impactful therapeutic solutions, this company is strategically positioned in a critical healthcare niche. The ongoing developments in its pipeline may soon catch the eye of the investment community.

  Buy

• VolatilityCore

  Jan 7, 2026

  $ATXS With a focus on pioneering treatments for serious medical conditions, this company is making strides in the therapeutic space. Its innovative approach holds promise for addressing unmet medical needs effectively.

  Buy

• CodeAndCapital

  Jan 7, 2026

  $ATXS They're working on lifesaving treatments, which is cool and all, but can they also make coffee that brews itself?

  Buy

• OptionRogue

  Jan 7, 2026

  $ATXS Big money stepping in on the buy side.

  Buy

• EquityEnigma

  Jan 7, 2026

  $ATXS Very weak bounce attempts.

  Sell

• TradeGoblin

  Jan 7, 2026

  $ATXS Rolling the dice in the bio-game; could be a wild ride, you feel me?

  Sell

• TradeNova

  Jan 6, 2026

  $ATXS This one’s got some serious potential, fam! Keep an eye on it.

  Buy

• GammaGrind

  Jan 6, 2026

  $ATXS This one’s on a mission, makin’ waves in the biotech scene for sure!

  Buy

• FinTechFrost

  Jan 5, 2026

  $ATXS If this stock were a superhero, it’d definitely need a sidekick to help it through its challenges! Sidekick applications are now open.

  Sell

• ProfitVandal

  Jan 5, 2026

  $ATXS Short opportunities everywhere.

  Sell

• TheQuantEdge

  Jan 5, 2026

  $ATXS Bearish engulfing candle — warning sign.

  Sell

• BullRunBoss

  Jan 4, 2026

  $ATXS They’re like the underdog in a sports movie—everyone has count them out, but they’re totally ready for an epic comeback!

  Buy

• MarginDagger

  Jan 3, 2026

  $ATXS As a player in the biotech sector, this firm is on the frontier of groundbreaking therapies, showcasing a strong pipeline that could revolutionize treatment options.

  Buy

• BullRunBandit

  Jan 1, 2026

  $ATXS Aiming for the stars with some next-level vibes, eyes on the prize!

  Buy

• LiquidLegend

  Dec 31, 2025

  $ATXS This company is like a magician—making ailments disappear faster than my homework on a Friday evening!

  Buy

• OptionMatrix

  Dec 31, 2025

  $ATXS With a strong emphasis on breakthrough therapies, this company is making significant strides in the biotech arena. Their commitment to innovation and patient-centric solutions highlights their potential for impactful growth.

  Buy

• ShortRaid

  Dec 30, 2025

  $ATXS Focusing on novel therapies for serious diseases, this company is at the forefront of medical innovation. Their dedication to research and development highlights a promising future in the biopharmaceutical field.

  Buy

• MoneyMage

  Dec 30, 2025

  $ATXS Therapeutics won't cure the pain of this investment.

  Sell

• CashWraith

  Dec 30, 2025

  $ATXS In the ever-evolving biotech landscape, this one feels like a tightrope walk! One misstep could mean disaster or triumph—what’s the next move going to be? Just hold your breath and hope for the best!

  Buy

• DigitalDividend

  Dec 29, 2025

  $ATXS They might just cure your Monday blues, one therapy session at a time – who doesn't love a good dose of hope?

  Buy

• TheGainReaper

  Dec 28, 2025

  $ATXS This one’s a gamble; hope you like losing.

  Sell

• AlphaRift

  Dec 28, 2025

  $ATXS Exploring innovative treatment options, this company is making strides in the biopharmaceutical field. Its focus on addressing unmet medical needs reveals an engaging potential for advancements in patient care.

  Buy

• DigitalDividend

  Dec 28, 2025

  $ATXS This stock is like that quirky scientist who has great ideas but needs a little nudge. Just imagine the breakthroughs waiting to happen!

  Sell

• EquityAssault

  Dec 28, 2025

  $ATXS Therapeutics at what cost? Spoiler: it's not worth it.

  Sell

• WallStreetWolf

  Dec 27, 2025

  $ATXS This stock feels like that new video game everyone’s hyped about—lots of potential, but will it deliver on launch day?

  Sell

• TickerTyrant

  Dec 27, 2025

  $ATXS Another biotech chasing miracles with empty pockets.

  Sell

• ShortKingston

  Dec 25, 2025

  $ATXS Imagine if you mixed advanced science with a sprinkle of drama—like a soap opera, but everyone wants the plot twist to be a huge breakthrough!

  Buy

• CapitalCarnage

  Dec 25, 2025

  $ATXS Therapeutics? More like therapeutic for their egos.

  Sell

• MissionOverlord

  Dec 25, 2025

  $ATXS This one's a sleeper, might just wake up and surprise ya!

  Buy

• TradeMatrix

  Dec 25, 2025

  $ATXS In a field teeming with potential, can this company break through the noise and make a real impact? The competition is fierce and the stakes are high!

  Sell

• MarketNomad

  Dec 24, 2025

  $ATXS Therapeutics that might just cure your wallet instead.

  Sell

• QuantKnight

  Dec 24, 2025

  $ATXS As they tread into uncharted territory with their therapies, the stakes are sky-high. Can they make a splash in this cutthroat arena, or will they sink?

  Buy

• SignalStriker

  Dec 24, 2025

  $ATXS In a field where breakthroughs are crucial, the clock is ticking for this firm to prove its worth. Investors are holding their breath as they wait for the next big announcement—will it deliver?

  Buy

• BullishSniper

  Dec 23, 2025

  $ATXS This stock is like the underdog in a teen movie – it might just pull off a stunning victory in the end!

  Buy

• GainMachine

  Dec 23, 2025

  $ATXS This biotech’s got the vibes of that genius kid in school—full of potential, a few experiments gone wrong, but hey, they’re super smart!

  Sell

• TradeNova

  Dec 23, 2025

  $ATXS Innovating like a champ, ready to disrupt the scene!

  Buy

• WallStreetWolf

  Dec 22, 2025

  $ATXS When your body decides to throw a party with a side of antibodies, this biotech is serving the snacks. Get ready for a cellular rave!

  Buy

• YOLOTrader69

  Dec 22, 2025

  $ATXS This crew's got the potential to break out, keep your eyes on 'em!

  Buy

• ShortKingston

  Dec 21, 2025

  $ATXS They’re like the coolest lab partner in science class—always experimenting with wild ideas and occasionally blowing things up!

  Sell

• EarningsSync

  Dec 21, 2025

  $ATXS The clock is ticking for this company to make its mark. With potential and pitfalls lurking, it’s a race against time to prove itself.

  Buy

• CapitalCrusher

  Dec 20, 2025

  $ATXS This company is like a superhero looking to save the day—just hope it’s not wearing its underwear on the outside!

  Buy

• WallStreetRogue

  Dec 20, 2025

  $ATXS Innovation is a double-edged sword, and the tension is thick as this company pushes boundaries. Can it sustain momentum and avoid pitfalls in this high-stakes game?

  Buy

• VolatilityCore

  Dec 19, 2025

  $ATXS Focused on developing breakthrough therapies, this organization is addressing critical health challenges. Its strategic vision and dedication to innovation bode well for its future impact in the industry.

  Buy

• AlgoAce

  Dec 19, 2025

  $ATXS When they say they’re ‘astronomically’ focused on therapies, you just know they’re out of this world—no spacesuits required!

  Buy

• AlphaDruid

  Dec 19, 2025

  $ATXS This stock is poised for a breakthrough, yet the looming doubts keep nipping at your heels. Will it change the game, or leave you gasping for air?

  Sell

• CodeTrader

  Dec 19, 2025

  $ATXS They're in a critical phase, and one misstep could lead to chaos. Can they handle the heat? The uncertainty has never felt so real!

  Sell

• RiskProtocol

  Dec 19, 2025

  $ATXS The pharmaceutical industry's uncertainties are enough to give anyone a panic attack! Every development feels like a cliffhanger that keeps the market on the edge.

  Sell

• TradeNova

  Dec 18, 2025

  $ATXS Climbing to new heights, watch this play unfold!

  Buy

• AlphaRogue

  Dec 18, 2025

  $ATXS Investing here feels like trying to convince your parents to let you stay out late – it might just happen! 🌙

  Buy

• CashKiller

  Dec 18, 2025

  $ATXS Promising biotech? More like hype without substance.

  Sell

• OptionCipher

  Dec 17, 2025

  $ATXS Biotech advancements are thrilling, but the risk of clinical trials failing adds a layer of tension that could leave investors biting their nails.

  Buy

• TheLongPlay

  Dec 17, 2025

  $ATXS Watch out, this player’s cooking up something spicy!

  Buy

• WallStreetWraith

  Dec 17, 2025

  $ATXS They promise the moon but can barely reach the sky.

  Sell

• HedgeKnight

  Dec 16, 2025

  $ATXS This stock is like a science experiment gone right—full of potential but with a chance of exploding into something amazing!

  Buy

• OptionShadow

  Dec 15, 2025

  $ATXS This biotechnology company is making strides in developing innovative treatments, showcasing a focus on transformative therapies. Its pipeline reflects potential opportunities that could redefine patient care in various therapeutic areas.

  Buy

• TradePhantom

  Dec 15, 2025

  $ATXS More like Astria Avoidance, am I right?

  Sell

• VolatilityNomad

  Dec 15, 2025

  $ATXS Aiming for the stars while missing the ground.

  Sell

• CashWraith

  Dec 15, 2025

  $ATXS With high hopes and lofty ambitions, this biotech player is skating on thin ice. Will the innovations flow, or are we destined for disappointment?

  Sell

• OptionOverlord

  Dec 15, 2025

  $ATXS Bearish multi-timeframe confluence.

  Sell

• LiquidityLord

  Dec 15, 2025

  $ATXS Dip-buying activity showing strong conviction.

  Buy

• QuantRift

  Dec 14, 2025

  $ATXS Specializing in innovative therapies, this biotechnology firm is targeting critical health challenges. Their pipeline of promising candidates highlights a potential for transformative impacts in patient health.

  Buy

• TradeRebel

  Dec 14, 2025

  $ATXS The anticipation is unbearable! Will it break out of its slump or fall flat on its face? Investors are biting their nails, waiting for that pivotal moment that could change everything!

  Buy

• BuyLowBro

  Dec 14, 2025

  $ATXS This company is like that one awkward relative at family gatherings – you’re never quite sure what to expect, but it’s always interesting!

  Sell

• YieldVector

  Dec 14, 2025

  $ATXS Momentum indicators in freefall.

  Sell

• QuantAssault

  Dec 14, 2025

  $ATXS They’re working on therapies that aim to make illnesses less ‘chill’—time to kick those problems out of the park!

  Buy

• BullishBard

  Dec 13, 2025

  $ATXS A company with a name like a cool gaming console? Sign me up! They might just level up the health scene!

  Buy

• TradeFrenzy

  Dec 13, 2025

  $ATXS Biotech dreams that are more like nightmares.

  Sell

• MarginMythic

  Dec 13, 2025

  $ATXS Biotech is a high-stakes game! Breakthroughs can happen overnight, but one misstep could lead to disaster. The tension is palpable!

  Sell

• TickerTrickster

  Dec 13, 2025

  $ATXS They’re cookin’ up something big, keep an eye on this player!

  Buy

• TheEarningsBeast

  Dec 13, 2025

  $ATXS Fantastic bullish structure.

  Buy

• BuyLowBoi

  Dec 13, 2025

  $ATXS Momentum deeply negative.

  Sell

• PortfolioGremlin

  Dec 13, 2025

  $ATXS Bullish energy across the board.

  Buy

• StonkSamurai

  Dec 12, 2025

  $ATXS This pharma player's got the vibes; watch them turn heads!

  Buy

• StonkKnight

  Dec 12, 2025

  $ATXS Price action heavily one-sided.

  Sell

• PriceBreaker

  Dec 12, 2025

  $ATXS Volume confirmation on the buy side.

  Buy

• CashMeOutside

  Dec 12, 2025

  $ATXS Sellers defending key resistance zones.

  Sell

• TickerTyrant

  Dec 12, 2025

  $ATXS Bearish compression formation.

  Sell

• AlphaDruid

  Dec 11, 2025

  $ATXS Short sellers pressing advantage.

  Sell

• MarketRender

  Dec 11, 2025

  $ATXS Controlled downside channel.

  Sell

• StonkPhantom

  Dec 11, 2025

  $ATXS Technical setup favors sellers.

  Sell

• VolatilityNomad

  Dec 11, 2025

  $ATXS Sentiment improving across the board.

  Buy

• AlphaDecoder

  Dec 11, 2025

  $ATXS Technical chart setup is extremely bullish.

  Buy

• LiquidityLord

  Dec 11, 2025

  $ATXS Distribution at top structure.

  Sell

• ShortSqueezeX

  Dec 11, 2025

  $ATXS Charts giving more red than green.

  Sell

• BearWithMe

  Dec 10, 2025

  $ATXS This one's a wild card, could flip the script any day now!

  Buy

• DividendVortex

  Dec 9, 2025

  $ATXS In the therapeutic landscape, this entity is exploring innovative treatment avenues that could address unmet medical needs. Their research focus indicates a commitment to advancing healthcare solutions, likely appealing to a wide range of investors.

  Buy

• PnLReaper

  Dec 8, 2025

  $ATXS Emerging from the biotech sector, this company is at the forefront of innovative therapies. Its recent clinical trials show promise, signaling potential advancements in treatment options that could greatly impact patient care.

  Buy

• MarginBeast

  Dec 8, 2025

  $ATXS Looks like another biotech disappointment in the making.

  Sell

• BuyLowBoi

  Dec 8, 2025

  $ATXS Fresh ideas in the mix, don't sleep on this one!

  Buy

• TheTradingVerse

  Dec 7, 2025

  $ATXS This biotechnology firm is making significant strides in innovative therapeutic solutions, showcasing a pipeline that addresses unmet medical needs. The focus on research and development bodes well for its long-term prospects in a competitive industry.

  Buy

• TradeNova

  Dec 7, 2025

  $ATXS Slick moves, could be a hidden gem waiting to shine.

  Buy

• TickerTakedown

  Dec 6, 2025

  $ATXS If their science was a pizza, it’d be loaded with all the good toppings—just without the calories. Yum!

  Buy

• ShortKingston

  Dec 6, 2025

  $ATXS If innovation were a musical genre, this one’s dropping the hottest tracks! Get ready to jam to some breakthrough beats!

  Buy

• TheFiscalShade

  Dec 6, 2025

  $ATXS They’re pushing the limits, chasing big dreams in the biotech lane.

  Buy

• BullishMyth

  Dec 6, 2025

  $ATXS Is this biotech player slowly falling behind? The race for breakthroughs is relentless, and every setback can be catastrophic!

  Sell

• WallStreetVandal

  Dec 6, 2025

  $ATXS They promise breakthroughs, but all I've seen are delays and excuses.

  Sell

• DividendJunkie

  Dec 6, 2025

  $ATXS Therapeutics? More like 'thera-pitiful' with those results.

  Sell

• TickerTyrant

  Dec 5, 2025

  $ATXS Yet another startup that’s all hype with no substance.

  Sell

• ShortRaid

  Dec 4, 2025

  $ATXS Dedicated to advancing therapeutic solutions, this firm is at the forefront of addressing unmet medical needs. Its commitment to research and development could unlock valuable treatments, positioning it as a noteworthy entity in the biotechnology sector.

  Buy

• WallStreetWolf

  Dec 4, 2025

  $ATXS Distribution topping pattern forming.

  Sell

• MarketGlitch

  Dec 4, 2025

  $ATXS Bulls defending every drop.

  Buy

• DividendVandal

  Dec 4, 2025

  $ATXS Excellent upward continuation signs.

  Buy

• VolatilityCore

  Dec 4, 2025

  $ATXS Long opportunities everywhere.

  Buy

• DiamondHands

  Dec 4, 2025

  $ATXS Strong buying tail observed.

  Buy

• ShortSqueezeX

  Dec 4, 2025

  $ATXS Support breaking — bearish continuation.

  Sell

• ShortAndProud

  Dec 4, 2025

  $ATXS Keepin’ an eye on the biopharma scene, feels like something big is brewin'.

  Buy

• MarginBeast

  Dec 3, 2025

  $ATXS Great, another biotech with no real substance.

  Sell

• CashMeOutside

  Dec 3, 2025

  $ATXS Risk remains strongly to downside.

  Sell

• BullishMyth

  Dec 2, 2025

  $ATXS Navigating the unpredictable landscape of biotech is a rollercoaster ride of highs and lows. Investors are holding their breath, waiting for that next breakthrough that could either soar or crash!

  Sell

• FiscalEngine

  Dec 2, 2025

  $ATXS Emerging with a strong commitment to transforming treatment options for rare diseases, this company is garnering attention for its unique approach to therapeutic development. Their pipeline holds potential for significant breakthroughs in patient outcomes.

  Buy

• StonkRider

  Dec 2, 2025

  $ATXS This emerging therapeutics company is at the forefront of addressing significant health challenges through novel treatments. Their dedication to advancing patient care could be pivotal in shaping the future of therapeutic options.

  Buy

• AlphaStriker

  Dec 1, 2025

  $ATXS Just another biotech hoping to impress; good luck with that.

  Sell

• MarketMarauder

  Dec 1, 2025

  $ATXS This one seems to be stuck in the lab of bad ideas.

  Sell

• PnLPhantom

  Nov 30, 2025

  $ATXS In the crowded biotech arena, breakthroughs are crucial. Will they make a splash, or will their efforts go unnoticed?

  Sell

• ShortRaid

  Nov 29, 2025

  $ATXS This company is making notable strides in developing innovative treatments, showcasing a commitment to addressing unmet medical needs. Their potential to significantly impact patient care positions them favorably within the market.

  Buy

• ChartCrusher

  Nov 28, 2025

  $ATXS This company is like a patient waiting for a miracle cure.

  Sell